Author

Garrett Sherwood

Observed names: G Sherwood, G. Sherwood, Garrett B Sherwood, Garrett B. Sherwood, Garrett Bernard Sherwood

Institution: Novant Health

Observed institutions: Novant Health, University of Alabama at Birmingham, Nanxi Mountain Hospital, Novant Health Forsyth Medical Center, UAB Medicine, Wake Forest University Health Sciences, Wake Forest University

OpenAlex ID: A5062877808

Rasburicase‐induced methemoglobinemia: case report, literature review, and proposed treatment algorithm

2016 · Garrett B. Sherwood, Rita D. Paschal, et al. · Clinical Case Reports · 26

Safety and efficacy of olomorasib + immunotherapy in first-line treatment of patients with KRAS G12C-mutant advanced NSCLC: Update from the LOXO-RAS-20001 trial.

2025 · Konstantin H. Dragnev, Yonina R. Murciano-Goroff, et al. · Journal of Clinical Oncology · 10

OA08.02 Efficacy and Safety of 1L Olomorasib + Chemoimmunotherapy in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01

2025 · M.V. Negrao, J.V. Uyeki, et al. · Journal of Thoracic Oncology · 7

Treatment of a Spinal Cord Hemitransection Injury with Keratin Biomaterial Hydrogel Elicits Recovery and Tissue Repair

2014 · Bailey V. Fearing, Christopher Hartley, et al. · ISRN Biomaterials · 7

1846MO Intracranial efficacy of olomorasib, a second-generation KRAS G12C inhibitor, in patients with KRAS G12C-mutant NSCLC who have active, untreated brain metastases

2025 · P. Cassier, J. Schneider, et al. · Annals of Oncology · 3

Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial

2026 · Megan E Daly, Charles B Simone, et al. · The Lancet · 1

Abstract 5434: Machine-learning-based epigenetic detection of early-stage lung cancers using the EpiCheck liquid biopsy platform

2023 · Dvir Netanely, Stephen Lam, et al. · Cancer Research · 1

Intracranial efficacy of olomorasib, a second-generation KRAS G12C inhibitor, in patients with KRAS G12C-mutant NSCLC who have active, untreated brain metastases

2026 · P Cassier, J Schneider, et al. · Pneumologie

Olomorasib+Chemoimmunotherapy in KRAS G12C-Mutant NSCLC: Results from LOXO-RAS-20001 and SUNRAY-01

2026 · M V Negrao, J V Uyeki, et al. · Pneumologie

Abstract C152: Bronchoscopy-informed recruitment to enhance equity in lung cancer clinical research: A pilot initiative at Novant Health oncology clinical research

2025 · Amnazo Muhirwa, Garrett Sherwood, et al. · Cancer Epidemiology Biomarkers & Prevention

To Evaluate a Proprietary Breath Analyzer in the Evaluation of High-risk Lung Nodules for Non-small Cell Lung Cancer: Single-center Feasibility Study

2024 · R.J. Cho, G. Peterson, et al.

P1.01-87 A Phase 1b Study of TRC105 In Combination with Paclitaxel/Carboplatin and Bevacizumab in Patients with Stage 4 Non-Squamous Cell Lung Cancer

2018 · F. Robert, M. Jerome, et al. · Journal of Thoracic Oncology

Effect of adequate hypomethylating agent (HMA) therapy on adverse prognostic factors in very elderly patients (>75 yrs) with myelodysplastic syndrome (MDS).

2016 · Vipin Lohiya, Garrett Sherwood, et al. · Journal of Clinical Oncology

Impact of Available Therapies on Survival of Very Elderly Myelodysplastic Syndrome (MDS) Patients (Age above 75 yrs)

2015 · Uma Borate, Vipin Lohiya, et al. · Blood

Works count: 14

Citation count: 55

H-index: 4

I10-index: 2